Gemcitabine Hydrochloride

CAS 122111-03-9 20 current records 10 historicalSmall Molecule

Who holds supplier records for Gemcitabine Hydrochloride? 20 organisations hold a current record for Gemcitabine Hydrochloride: an active US FDA Type II Drug Master File or a CEP. A further 10 organisations have only historical (inactive) DMF filings. 15 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (12), China (4), Netherlands (1), Spain (1) and 2 other countries (2).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Gemcitabine Hydrochloride: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/gemcitabine-hydrochloride

Reading the evidence

  • 20 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    12 of the 20 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 9 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (20)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Gemcitabine Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Gemcitabine Hydrochloride sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (15)

Certificates of Suitability on the EDQM register for Gemcitabine Hydrochloride, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 29 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
GRAND WUYAO (JIANGSU) PHARMACEUTICAL CO. LTD. LianyungangCN
CEP 2025-157 - Rev 00
Gemcitabine hydrochloride
Jun 2026—
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
CEP 2007-021 - Rev 03
Gemcitabine hydrochloride
Mar 2026—
HETERO LABS LIMITED HyderabadIN
CEP 2022-499 - Rev 01
Gemcitabine hydrochloride, GA process
Feb 2026—
INTAS PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2022-092 - Rev 03
Gemcitabine hydrochloride, Process III
Feb 2026—
RAVI BIOLIFE PRIVATE LIMITED MumbaiIN
CEP 2023-229 - Rev 01
Gemcitabine hydrochloride
Dec 2025—
LAURUS LABS LIMITED HyderabadIN
CEP 2025-445 - Rev 00
Gemcitabine hydrochloride, Process-3
Nov 2025—
SHILPA PHARMA LIFESCIENCES LIMITED RaichurIN
CEP 2006-222 - Rev 02
Gemcitabine hydrochloride
Jul 2025—
FARMHISPANIA S.A. MontmelóES
CEP 2024-203 - Rev 00
Gemcitabine hydrochloride
Jun 2025Inspected May 2023
Spain, outside 3-year window
TAPI NL B.V. AmsterdamNL
CEP 2008-161 - Rev 03
Gemcitabine hydrochloride
May 2025—
FRESENIUS KABI ONCOLOGY LIMITED KalyaniIN
CEP 2008-131 - Rev 05
Gemcitabine hydrochloride
Nov 2024—
SCINOPHARM TAIWAN LTD. Shan-HuaTW
CEP 2006-272 - Rev 07
Gemcitabine hydrochloride
Sept 2024—
JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. Lianyungang CityCN
CEP 2017-076 - Rev 01
Gemcitabine hydrochloride
Sept 2024—
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
R1-CEP 2007-075 - Rev 06
Gemcitabine hydrochloride
Jun 2021—
FUAN PHARMACEUTICAL GROUP NINGBO TEAM PHARMACEUTICAL CO., LTD. NingboCN
R1-CEP 2009-042 - Rev 01
Gemcitabine hydrochloride
Oct 2015—
Eli Lilly And Company IndianapolisUS
R1-CEP 2007-063 - Rev 00
Gemcitabine hydrochloride
Nov 2014—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (10)

Organisations whose Type II DMFs for Gemcitabine Hydrochloride are no longer active. These show a past filing, not current supply.

Show all 10 historical records
  • DISHMAN PHARMACEUTICALS AND CHEMICALS LTD
    Inactive DMF 27649 · filed Oct 2013
  • India · Inactive DMF 27442 · filed Sept 2013
  • China · Inactive DMF 24893 · filed Apr 2011
  • JARI PHARMACEUTICAL CO LTD
    Inactive DMF 24341 · filed Oct 2010
  • Taiwan · Inactive DMF 24278 · filed Oct 2010
  • MYLAN LABORATORIES LTD
    Inactive DMF 23833 · filed May 2010
  • Italy · Inactive DMF 23516 · filed Feb 2010
  • India · Inactive DMF 23433 · filed Jan 2010
  • Italy · Inactive DMF 22199 · filed Oct 2008
  • BENZOCHEM LIFESCIENCES PVT LTD
    Inactive DMF 21274 · filed Jan 2008

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Gemcitabine Hydrochloride is a nucleoside analog used as chemotherapy. It is primarily utilized in the treatment of various carcinomas, including non-small cell lung cancer and pancreatic cancer.

Chemical identity

IUPAC name
4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
Canonical SMILES
C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F.Cl
InChIKey
OKKDEIYWILRZIA-OSZBKLCCSA-N
Synonyms
Gemzar API, avgemsi, gemcitabine (as hydrochloride), gemcitabine hcl, gemzar, infugem, inlexzo, ly-188011 hydrochloride, ly188011 hydrochloride

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Nucleoside Metabolic Inhibitor
Mechanism of action
Nucleic Acid Synthesis Inhibitors

Therapeutic areas

OncologyHematology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Gemcitabine Hydrochloride?

20 organisations hold an active US FDA Type II Drug Master File or a CEP for Gemcitabine Hydrochloride: Intas Pharmaceuticals Ltd. (India), SHILPA PHARMA LIFESCIENCES LTD (India), TAPI NL BV (Netherlands), ARCH PHARMALABS LTD (India), Emcure Pharmaceuticals Limited (India), Dr. Reddy's Laboratories Ltd. (India), FARMHISPANIA SA (Spain) and Hetero Labs Limited (India), and 12 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Gemcitabine Hydrochloride Drug Master Files are active?

Intas Pharmaceuticals Ltd. (DMF 22748, 36573), SHILPA PHARMA LIFESCIENCES LTD (DMF 31892, 24136), TAPI NL BV (DMF 27402, 20979), ARCH PHARMALABS LTD (DMF 23633, 23801), Emcure Pharmaceuticals Limited (DMF 23339, 27617), Dr. Reddy's Laboratories Ltd. (DMF 18857), FARMHISPANIA SA (DMF 40133) and Hetero Labs Limited (DMF 22229) and 8 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Gemcitabine Hydrochloride records mean?

10 organisations have only inactive Type II DMFs for Gemcitabine Hydrochloride. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Gemcitabine Hydrochloride have a European Certificate of Suitability?

Yes. 15 organisations hold a valid CEP for Gemcitabine Hydrochloride on the EDQM register, including GRAND WUYAO (JIANGSU) PHARMACEUTICAL CO. LTD. Lianyungang (CN), SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN), HETERO LABS LIMITED Hyderabad (IN), INTAS PHARMACEUTICALS LIMITED Ahmedabad (IN), RAVI BIOLIFE PRIVATE LIMITED Mumbai (IN) and LAURUS LABS LIMITED Hyderabad (IN) and 9 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Gemcitabine Hydrochloride supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Gemcitabine Hydrochloride?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.